Pub Date : 2024-01-01Epub Date: 2024-10-29DOI: 10.1080/14796678.2024.2411191
Chandrashekar Bohra, Amit Gulati, Amit Hooda
{"title":"Coronary intravascular lithotripsy: the tombstone of coronary calcium.","authors":"Chandrashekar Bohra, Amit Gulati, Amit Hooda","doi":"10.1080/14796678.2024.2411191","DOIUrl":"10.1080/14796678.2024.2411191","url":null,"abstract":"","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"669-670"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-01-15DOI: 10.2217/fca-2023-0130
Ashling Cannon
{"title":"Get pumped for the new year with <i>Future Cardiology</i>: welcome to volume 20.","authors":"Ashling Cannon","doi":"10.2217/fca-2023-0130","DOIUrl":"10.2217/fca-2023-0130","url":null,"abstract":"","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-4"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139466415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-05-06DOI: 10.1080/14796678.2024.2340919
Devin Skoll, Phillip Abarca, Vu Pham, Anushka Das, Clark Mantini, Han Tun, Helga Van Herle, Ajay Vaidya, Aaron M Wolfson, Michael W Fong
Introduction: Accurate volume status monitoring is crucial for effective diuretic therapy in patients with acute decompensated heart failure (ADHF). While guidelines recommend daily standing body weight measurement as an indicator of volume status, bed scales are commonly used in healthcare facilities.Methods: A method-comparison design was used to compare bed and standing scale weights among adults hospitalized with ADHF at Los Angeles County-University of Southern California Medical Center between March and April 2023.Results & Conclusion: Among 51 weight pairs from 43 participants, a clinically significant mean difference of 1.42 ± 1.18 kg was observed, exceeding the recommended threshold. Inaccuracies, with 71% showing differences >0.6 kg, highlight potential fluid management errors when relying on bed scales in ADHF hospitalizations.
{"title":"Accuracy and correlation of bed and standing scale weights in monitoring volume status in heart failure patients.","authors":"Devin Skoll, Phillip Abarca, Vu Pham, Anushka Das, Clark Mantini, Han Tun, Helga Van Herle, Ajay Vaidya, Aaron M Wolfson, Michael W Fong","doi":"10.1080/14796678.2024.2340919","DOIUrl":"10.1080/14796678.2024.2340919","url":null,"abstract":"<p><p><b>Introduction:</b> Accurate volume status monitoring is crucial for effective diuretic therapy in patients with acute decompensated heart failure (ADHF). While guidelines recommend daily standing body weight measurement as an indicator of volume status, bed scales are commonly used in healthcare facilities.<b>Methods:</b> A method-comparison design was used to compare bed and standing scale weights among adults hospitalized with ADHF at Los Angeles County-University of Southern California Medical Center between March and April 2023.<b>Results & Conclusion:</b> Among 51 weight pairs from 43 participants, a clinically significant mean difference of 1.42 ± 1.18 kg was observed, exceeding the recommended threshold. Inaccuracies, with 71% showing differences >0.6 kg, highlight potential fluid management errors when relying on bed scales in ADHF hospitalizations.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"389-393"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457616/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140859977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-07-01DOI: 10.1080/14796678.2024.2363063
Takamasa Tanaka, Kenji Kawai, Christopher R Ellis, Mukta Srivastava, Rika Kawakami, Takao Konishi, Tatsuya Shiraki, Teruo Sekimoto, Renu Virmani, Aloke V Finn
Oral anticoagulation therapy (OAC) is a mainstay for mitigating stroke and other embolic events in patients with atrial fibrillation (AF). Despite the demonstrated efficacy of OAC in reducing events, many patients are unable to tolerate OAC due to bleeding risks. Left atrial appendage occlusion (LAAO) devices were developed as implantable technologies to moderate stroke risk in patients with intolerance to OAC. Despite clinical data supporting near-comparable protection against thromboembolic events with OAC, device-related thrombus formation has emerged as a critical complication following LAAO that remains a potential limitation to the safety and efficacy of LAAO. Improved biocompatibility of LAAO devices with fluoropolymers, a well-established stent-coating technology used to reduce thrombus formation and promote endothelialization, may optimize outcomes after LAAO.
{"title":"Challenges and advances in device-related thrombus in left atrial appendage occlusion.","authors":"Takamasa Tanaka, Kenji Kawai, Christopher R Ellis, Mukta Srivastava, Rika Kawakami, Takao Konishi, Tatsuya Shiraki, Teruo Sekimoto, Renu Virmani, Aloke V Finn","doi":"10.1080/14796678.2024.2363063","DOIUrl":"10.1080/14796678.2024.2363063","url":null,"abstract":"<p><p>Oral anticoagulation therapy (OAC) is a mainstay for mitigating stroke and other embolic events in patients with atrial fibrillation (AF). Despite the demonstrated efficacy of OAC in reducing events, many patients are unable to tolerate OAC due to bleeding risks. Left atrial appendage occlusion (LAAO) devices were developed as implantable technologies to moderate stroke risk in patients with intolerance to OAC. Despite clinical data supporting near-comparable protection against thromboembolic events with OAC, device-related thrombus formation has emerged as a critical complication following LAAO that remains a potential limitation to the safety and efficacy of LAAO. Improved biocompatibility of LAAO devices with fluoropolymers, a well-established stent-coating technology used to reduce thrombus formation and promote endothelialization, may optimize outcomes after LAAO.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"343-358"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-07-10DOI: 10.1080/14796678.2024.2343592
Fadi Hage, Ali Hage, Manuel R Cervetti, Michael W A Chu
Mitral valve repair is the ideal intervention for mitral valve disease with excellent long-term survival comparable to the age-matched general population. When the mitral valve is not repairable, mechanical prostheses may be associated with improved survival as compared with biological prostheses. Newer mechanical and biological valve prostheses have the potential to improve outcomes following mitral valve replacement in young patients. Patients presenting for mitral valve surgery after failed transcatheter mitral valve-in-valve have high rates of postoperative mortality and morbidity, exceeding those seen with reoperative mitral valve surgery, which poses issues in young patients who have a higher cumulative incidence of reintervention.
{"title":"Mitral valve replacement in young patients: review and current challenges.","authors":"Fadi Hage, Ali Hage, Manuel R Cervetti, Michael W A Chu","doi":"10.1080/14796678.2024.2343592","DOIUrl":"10.1080/14796678.2024.2343592","url":null,"abstract":"<p><p>Mitral valve repair is the ideal intervention for mitral valve disease with excellent long-term survival comparable to the age-matched general population. When the mitral valve is not repairable, mechanical prostheses may be associated with improved survival as compared with biological prostheses. Newer mechanical and biological valve prostheses have the potential to improve outcomes following mitral valve replacement in young patients. Patients presenting for mitral valve surgery after failed transcatheter mitral valve-in-valve have high rates of postoperative mortality and morbidity, exceeding those seen with reoperative mitral valve surgery, which poses issues in young patients who have a higher cumulative incidence of reintervention.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"409-417"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457673/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141563147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-07-23DOI: 10.1080/14796678.2024.2377924
Lei Tian, Su Zhao, Ruiyan Zhang
Aim: To explore potential value of inter-alpha-trypsin inhibitor heavy chain-4 (ITIH4) for coronary artery disease (CAD) diagnosis.Patients & methods: We recruited the patients who received coronary arteriography (CAG) examination. The enzyme-linked immunosorbent assay was used to detect plasma ITIH4.Results: ITIH4 level was lower expression in CAD patients than that in patients of control group, and was negatively correlated with C-reactive protein (CRP). ITIH4 level is no differences between ST-elevated myocardial infarction (STEMI) and non-ST-elevated myocardial infarction (NSTEMI) patients. However, its expression was significantly correlated with D-Dimer and thrombin time, and the logistic analysis confirmed predictive value of ITIH4 for visible thrombus in coronary.Conclusion: ITIH4 may be a useful biomarker in CAD diagnosis, and to predict visible thrombus in coronary.
{"title":"ITIH4 is a predictor for coronary thrombus in coronary arteriography patients.","authors":"Lei Tian, Su Zhao, Ruiyan Zhang","doi":"10.1080/14796678.2024.2377924","DOIUrl":"10.1080/14796678.2024.2377924","url":null,"abstract":"<p><p><b>Aim:</b> To explore potential value of inter-alpha-trypsin inhibitor heavy chain-4 (ITIH4) for coronary artery disease (CAD) diagnosis.<b>Patients & methods:</b> We recruited the patients who received coronary arteriography (CAG) examination. The enzyme-linked immunosorbent assay was used to detect plasma ITIH4.<b>Results:</b> ITIH4 level was lower expression in CAD patients than that in patients of control group, and was negatively correlated with C-reactive protein (CRP). ITIH4 level is no differences between ST-elevated myocardial infarction (STEMI) and non-ST-elevated myocardial infarction (NSTEMI) patients. However, its expression was significantly correlated with D-Dimer and thrombin time, and the logistic analysis confirmed predictive value of ITIH4 for visible thrombus in coronary.<b>Conclusion:</b> ITIH4 may be a useful biomarker in CAD diagnosis, and to predict visible thrombus in coronary.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"547-554"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485701/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-08-19DOI: 10.1080/14796678.2024.2385872
Shaunak Mangeshkar, Pawel Borkowski, Nikita Singh, Panagiotis Zoumpourlis, Maisha Maliha, Sanjana Nagraj, Amrin Kharawala, Robert Faillace
Chronic thromboembolic pulmonary hypertension (CTEPH) is an underdiagnosed sequela of acute pulmonary embolism with varied clinical presentation causing significant morbidity among the affected population. There exist important differences in the occurrence, clinical features and diagnosis of CTEPH between men and women, with women carrying a greater predisposition for the disease. Ongoing studies have also pointed out variations among men and women, in the treatment offered and long-term outcomes including mortality. This focused review article highlights important sex-associated differences in multiple aspects of CTEPH including its epidemiology, clinical features, diagnosis, treatment and outcomes as reported in current literature and highlights the need for future research to facilitate a clearer understanding of these differences.
{"title":"Sex differences in Chronic Thromboembolic Pulmonary Hypertension.","authors":"Shaunak Mangeshkar, Pawel Borkowski, Nikita Singh, Panagiotis Zoumpourlis, Maisha Maliha, Sanjana Nagraj, Amrin Kharawala, Robert Faillace","doi":"10.1080/14796678.2024.2385872","DOIUrl":"10.1080/14796678.2024.2385872","url":null,"abstract":"<p><p>Chronic thromboembolic pulmonary hypertension (CTEPH) is an underdiagnosed sequela of acute pulmonary embolism with varied clinical presentation causing significant morbidity among the affected population. There exist important differences in the occurrence, clinical features and diagnosis of CTEPH between men and women, with women carrying a greater predisposition for the disease. Ongoing studies have also pointed out variations among men and women, in the treatment offered and long-term outcomes including mortality. This focused review article highlights important sex-associated differences in multiple aspects of CTEPH including its epidemiology, clinical features, diagnosis, treatment and outcomes as reported in current literature and highlights the need for future research to facilitate a clearer understanding of these differences.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"571-580"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485851/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2023-12-19DOI: 10.2217/fca-2023-0095
Saint-Martin Allihien, Sammudeen Ibrahim, Favour Markson, Walter Y Agyeman, Setri Fugar, Onoriode Kesiena
Aim: Coronary heart disease (CHD) increases the risk of adverse outcomes from invasive pneumococcal disease. Methods: Using the 2020 and 2021 data from the national health interview survey, we identified adults with CHD. Chi-square analysis and logistic regression were used to examine factors that influence vaccination status. Results: There were 2675 participants aged 41 and above with CHD. Participants were predominantly white people (82.5%) and males (60.1%). The odds of receiving the pneumococcal vaccine increased with stepwise increase in comorbidities from 1 to 2 and from 2 to 3. Among individuals with ≥2 comorbidities, black people were less likely to be vaccinated compared with white people. Conclusion: Pneumococcal vaccine uptake among adults with CHD is determined by cumulative comorbidities and ethnicity.
{"title":"The impact of comorbidities and sociodemographic predictors on pneumococcal vaccination coverage in adults with coronary heart disease.","authors":"Saint-Martin Allihien, Sammudeen Ibrahim, Favour Markson, Walter Y Agyeman, Setri Fugar, Onoriode Kesiena","doi":"10.2217/fca-2023-0095","DOIUrl":"10.2217/fca-2023-0095","url":null,"abstract":"<p><p><b>Aim:</b> Coronary heart disease (CHD) increases the risk of adverse outcomes from invasive pneumococcal disease. <b>Methods:</b> Using the 2020 and 2021 data from the national health interview survey, we identified adults with CHD. Chi-square analysis and logistic regression were used to examine factors that influence vaccination status. <b>Results:</b> There were 2675 participants aged 41 and above with CHD. Participants were predominantly white people (82.5%) and males (60.1%). The odds of receiving the pneumococcal vaccine increased with stepwise increase in comorbidities from 1 to 2 and from 2 to 3. Among individuals with ≥2 comorbidities, black people were less likely to be vaccinated compared with white people. <b>Conclusion:</b> Pneumococcal vaccine uptake among adults with CHD is determined by cumulative comorbidities and ethnicity.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"11-19"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138800822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-09-27DOI: 10.1080/14796678.2024.2404775
Vincent S Alexander, Andrew D Vogel, Zachary T Silvano, Herra Javed, Alekhya Mitta, Taufiek Konrad Rajab
Partial heart transplantation (PHT) has emerged as a new treatment strategy to correct unrepairable heart valve dysfunction in pediatric patients. PHT selectively replaces the dysfunctional components of the recipient's heart and spares the native ventricles. As a result, the transplant biology of PHTs differs from heart transplants. Notably, donor hearts that are unsuitable for whole heart transplantation can be used, graft preservation can be prolonged and immunosuppression levels can be lowered. These nuances of PHT transplant biology have important implications for organizational aspects of PHT clinical application.
{"title":"Organizational challenges for partial heart transplantation.","authors":"Vincent S Alexander, Andrew D Vogel, Zachary T Silvano, Herra Javed, Alekhya Mitta, Taufiek Konrad Rajab","doi":"10.1080/14796678.2024.2404775","DOIUrl":"10.1080/14796678.2024.2404775","url":null,"abstract":"<p><p>Partial heart transplantation (PHT) has emerged as a new treatment strategy to correct unrepairable heart valve dysfunction in pediatric patients. PHT selectively replaces the dysfunctional components of the recipient's heart and spares the native ventricles. As a result, the transplant biology of PHTs differs from heart transplants. Notably, donor hearts that are unsuitable for whole heart transplantation can be used, graft preservation can be prolonged and immunosuppression levels can be lowered. These nuances of PHT transplant biology have important implications for organizational aspects of PHT clinical application.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"719-728"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01Epub Date: 2024-08-07DOI: 10.1080/14796678.2024.2384239
Stefano De Servi, Antonio Landi
{"title":"A new goal for secondary prevention of cardiovascular diseases: the reduction of neutrophil count.","authors":"Stefano De Servi, Antonio Landi","doi":"10.1080/14796678.2024.2384239","DOIUrl":"10.1080/14796678.2024.2384239","url":null,"abstract":"","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"517-519"},"PeriodicalIF":1.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141897251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}